Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Replimune Group Inc (NASDAQ:REPL) announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 (vusolimogene oderparepvec) combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).
- The overall response rate (ORR) was 36%, and the complete response (CR) rate was 20% compared to the 12.5% shown in the prior 16 patients presented in June 2022.
- Safety data with RP1 + nivolumab continues to demonstrate an attractive safety profile, with predominantly ‘on target' Grade 1-2 side effects indicative of systemic immune activation.
- The Company also provided new data from the ongoing Phase 1 clinical trial evaluating RP2 and RP3, demonstrating promising early signals in metastatic tumors and multiple soft tissue sarcomas.
- Concurrently, Replimune announced a clinical trial and supply agreement for its RP2/3 program in colorectal cancer (CRC) and hepatocellular carcinoma (HCC) with Roche Holdings AG (OTC: RHHBY).
- Specifically, the companies will collaborate in third-line (3L) CRC and first- and second-line (1L & 2L) HCC.
- Under the terms of the agreement, the companies will share costs, and Roche will supply its currently approved drugs, atezolizumab, and bevacizumab.
- Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023.
- Price Action: REPL shares are up 16.10% at $21.94 on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!